Emergent BioSolutions Secures Over $60 Million in Smallpox Countermeasure Contracts

Emergent BioSolutions (NYSE: EBS) has announced securing new contracts and orders worth over $60 million for its smallpox medical countermeasure, VIGIV. The primary component is a $54 million contract from the U.S. government, exercised as an option under an existing 10-year agreement. This contract was awarded by the Administration for Strategic Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services. In addition to the domestic award, the company also secured orders from an unnamed international government partner. These agreements are part of a broader strategy to maintain preparedness against potential smallpox outbreaks. This development provides significant financial visibility for the biotech firm and reinforces its position as a critical government supplier.

Sources:globenewswire.comstocktitan.nettipranks.comopenpr.commorningstar.comcitybiz.couk.investing.comstreetinsider.cominvestors.emergentbiosolutions.cominvesting.comgurufocus.combenzinga.com